Head-to-head evidence
Icotinib vs TY-9591
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Icotinib
Developed by Betta Pharmaceuticals Co.
NCT01040780 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.
Next expected readout: December 2030 · NCT06955325 (registry estimate)
TY-9591
Developed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icotinib's landscape · TY-9591's landscape